- Analytical Chemistry and Pharmacology (ACP) Shared Resource The goals of the Analytical Chemistry and Pharmacology SR (ACP) are to support the translational development of small molecule, nanoparticle and biological anticancer agents via analytical chemistry and pharmacologic infrastructure, methodologies and expertise. The expansion of the Molecular Therapeutics Program, development of preclinical models to evaluate anticancer agents, the opening of the new North Carolina Cancer Hospital?s (NCCH) Clinical Trials Unit (CTU) and recruitment of additional faculty members to the UNC LCCC and Carolina Institute for NanoMedicine (CINM) created increased demand for applied and translational pharmacology services. This SR is comprised of the Translational Oncology and Nanoparticle Drug Development Initiative (TOND2I) Lab and the sample processing lab located in the NCCH CTU. The SR develops and validates analytical assays in biological solutions, analyzes samples, performs pharmacokinetic and pharmacodynamic analyses of data for small molecule agents and provides specialized methods to evaluate the pharmacology of carrier-mediated agents (e.g. nanoparticle, conjugates, antibody drug conjugates) and biologics. The ACP supports studies throughout the UNC LCCC with extensive use by the Breast Cancer, Molecular Therapeutics, Cancer Cell Biology, Immunology and Clinical and Translational Research programs in the UNC LCCC. In addition, the ACP has significant collaborations with UNC LCCC members that are also part of the Carolina Institute for NanoMedicine (CINM), Carolina Center for Cancer Nanotechnology Excellence (C-CCNE) and the Center for Integrative Chemical Biology and Drug Discover (CICBDD), Center for Nanotechnology in Drug Delivery (CNDD) and the Center for Pharmacogenomics and Individualized Therapy (CPIT) in the UNC School of Pharmacy. The SR is currently being used by 14 investigators, 74% of whom are peer reviewed cancer center members. The total budget for the SR is $588,141 and $77,823 (13% of the total budget) is requested from the CCSG. Future plans are to expand the research of UNC LCCC members, develop novel pharmacologic methods and platforms and use the resources of this SR to recruit novel anticancer agents to UNC translational and clinical development.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-43
Application #
9614906
Study Section
Subcommittee I - Career Development (NCI)
Project Start
Project End
Budget Start
2018-12-01
Budget End
2019-11-30
Support Year
43
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Dhungel, Bal Mukunda; Montgomery, Nathan D; Painschab, Matthew S et al. (2018) 'Discovering' primary effusion lymphoma in Malawi. AIDS 32:2264-2266
Cameron, Jennifer E; Rositch, Anne F; Vielot, Nadja A et al. (2018) Epstein-Barr Virus, High-Risk Human Papillomavirus and Abnormal Cervical Cytology in a Prospective Cohort of African Female Sex Workers. Sex Transm Dis 45:666-672
Lim, Joseph K; Liapakis, Ann Marie; Shiffman, Mitchell L et al. (2018) Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Clin Gastroenterol Hepatol 16:1811-1819.e4
Wang, Gary P; Terrault, Norah; Reeves, Jacqueline D et al. (2018) Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. Sci Rep 8:3199
Phillips, Bonnie; Van Rompay, Koen K A; Rodriguez-Nieves, Jennifer et al. (2018) Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques. J Virol 92:
Lianga, Noel; Doré, Carole; Kennedy, Erin K et al. (2018) Cdk1 phosphorylation of Esp1/Separase functions with PP2A and Slk19 to regulate pericentric Cohesin and anaphase onset. PLoS Genet 14:e1007029
Allott, Emma H; Geradts, Joseph; Cohen, Stephanie M et al. (2018) Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Res 20:12
Agle, Kimberle; Vincent, Benjamin G; Piper, Clint et al. (2018) Bim regulates the survival and suppressive capability of CD8+ FOXP3+ regulatory T cells during murine GVHD. Blood 132:435-447
Puvanesarajah, Samantha; Nyante, Sarah J; Kuzmiak, Cherie M et al. (2018) PAM50 and Risk of Recurrence Scores for Interval Breast Cancers. Cancer Prev Res (Phila) 11:327-336
Stanley, Christopher C; van der Gronde, Toon; Westmoreland, Kate D et al. (2018) Risk factors and reasons for treatment abandonment among children with lymphoma in Malawi. Support Care Cancer 26:967-973

Showing the most recent 10 out of 1525 publications